Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial

• Andrew H. Wei,
• Gail J. Roboz,
• Herve Dombret,
• Hartmut Dohner,
• Andre C. Schuh,
• Pau Montesinos,
• Dominik Selleslag,
• Sergey N. Bondarenko,
• Thomas Prebet,
• Yinzhi Lai,
• Barry Skikne,
• C.L. Beach,
• Farhad Ravandi

Affiliations

Andrew H. Wei

Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne

Gail J. Roboz

Weill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, New York, NY

Herve Dombret

Hematology, Hopital Saint-Louis, Assistance Publique – Hopitaux de Paris (AP-HP), Paris, France; Institut de Recherche Saint-Louis, Universite Paris Cite, Paris

Hartmut Dohner

Department of Internal Medicine III, Ulm University Hospital, Ulm

Andre C. Schuh

Princess Margaret Cancer Centre, Toronto, ON

Pau Montesinos

Hospital Universitario y Politecnico La Fe, Valencia

Dominik Selleslag

AZ Sint-Jan Brugge-Oostende AV, Bruges

Sergey N. Bondarenko

RM Gorbacheva Research Institute, Pavlov University, St. Petersburg

Thomas Prebet

Bristol Myers Squibb, Summit, NJ

Yinzhi Lai

Bristol Myers Squibb, Summit, NJ

Barry Skikne

Bristol Myers Squibb, Summit, NJ, USA; University of Kansas Cancer Center, Kansas City, KS

C.L. Beach

Bristol Myers Squibb, Summit, NJ

Farhad Ravandi

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX